申请人:Habashita Hiromu
公开号:US20060004010A1
公开(公告)日:2006-01-05
A compound of formula (I) or a salt thereof, and medical use thereof (the symbols in the formula are as described in the specification).
The compound of formula (I) has CCR4 antagonistic activity, and therefore is useful as a preventive and/or therapeutic agent for diseases associated with CCR4, i.e., CCR4-mediated diseases such as inflammatory and/or allergic diseases [e.g., systemic inflammatory response syndrome (SIRS), anaphylaxis or anaphylaxis-like reaction, allergic vasculitis, reject reaction for graft organ, hepatitis, nephritis, nephrosis, pancreatitis, rhinitis, arthritis, inflammatory ocular diseases, inflammatory bowel diseases, diseases in cerebro and/or circulatory system, respiratory diseases, dermatic diseases, autoimmune diseases, etc.], and the like.
化合物式(I)或其盐,并且其医疗用途(式中的符号如说明书所述)。化合物式(I)具有CCR4拮抗活性,因此可用作预防和/或治疗CCR4相关的疾病的药物,即CCR4介导的疾病,例如炎症和/或过敏性疾病[例如全身炎症反应综合征(SIRS),过敏性休克或类似休克反应,过敏性血管炎,移植器官排斥反应,肝炎,肾炎,肾病综合征,胰腺炎,鼻炎,关节炎,炎症性眼部疾病,炎症性肠病,大脑和/或循环系统疾病,呼吸系统疾病,皮肤疾病,自身免疫性疾病等]等。